ctrl K

Price Alert

Enanta Pharmaceuticals In... (ENTA)

NASDAQ: ENTA · Real-Time Price · USD

8.47

0.30 (3.67%)

At close: Aug 19, 2025, 12:10 PM

Enanta Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	37.23M	85.39M	43.99M	57.21M
Short-Term Investments	210.95M	284.52M	205.24M	186.8M
Long-Term Investments	3.36M	3.97M	29.29M	108.42M
Other Long-Term Assets	94K	803K	-516K	-1.37M
Receivables	38.65M	39.62M	49.04M	60.83M
Inventory	n/a	n/a	n/a	n/a
Other Current Assets	608K	n/a	n/a	n/a
Total Current Assets	299.85M	422.79M	311.71M	319.02M
Property-Plant & Equipment	73.35M	34.71M	29.75M	10.65M
Goodwill & Intangibles	n/a	n/a	n/a	n/a
Total Long-Term Assets	76.8M	39.48M	63.7M	119.77M
Total Assets	376.65M	462.27M	375.41M	438.79M
Account Payables	8M	4.1M	6M	9.54M
Deferred Revenue	n/a	n/a	n/a	n/a
Short-Term Debt	34.46M	35.08M	2.89M	4.2M
Other Current Liabilities	n/a	n/a	-2.89M	-4.2M
Total Current Liabilities	57.53M	62.79M	29.83M	36.17M
Long-Term Debt	136.13M	160.85M	1.42M	1.51M
Other Long-Term Liabilities	231K	663K	454K	558K
Total Long-Term Liabilities	190.3M	182.75M	24.25M	3.19M
Total Liabilities	247.84M	245.54M	54.08M	39.36M
Total Debt	226.06M	26.51M	25.26M	5.33M
Common Stock	212K	211K	208K	202K
Retained Earnings	-323.04M	-207M	-73.18M	48.58M
Comprehensive Income	302K	-1.17M	-3.72M	-382K
Shareholders Equity	128.81M	216.74M	321.33M	399.43M
Total Investments	210.95M	284.52M	234.52M	295.21M